Content
57
Yahoo Finance
06/04
(Community Post)
Hey Donny.....you love to make deals right??? How about I trade you 100 shares of Gercon for 10 McDonald's chicken nuggets..... what do you say??? Deal or no deal??? Pooooooopstain and Hodl Baggy Hodl thinks it would be a great deal for you!!! 😂 ...
60
Nasdaq
06/04
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)
Geron (GERN) has been beaten down lately with too much selling pressure. While the stock has lost 26.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold…...
57
Yahoo Finance
06/04
(Community Post)
IMO will see PPS manipulation right up to the the they estimate P3 results are released, My guess Prior AUG-Sept 3-4 PPS maybe sooner Fair market evaluation ranges 7 bucks PPS or so, Id be concerned if Inst start selling, From Fintel institutional Shares (Long)526,142,156 - 82.01% (ex 13D/G) - change of 37.65MM shares 7.71% MRQ Institutional Value (Long)$ 773,581 USD ($1000) JMHO...
Votes:
4
0
57
Yahoo Finance
06/04
(Community Post)
From In May 2026 Here s just a few recent filings, Morgan Stanley stands out over 12 Mil shares, Eversept Partners, LP 18.8 Mil Shares Millennium Partners over 7 Mil , Vanguard Capital over 26 Mil shares, Heres a name Citadel Partners Over 21 Mil Shares, Point 72 Asset Management over 20 Mil shares, Get This State Street Over 30 Mil shares Again May just reported May 15 2026 Source Fintel , On the Sell Side GS stands out selling over 11 Mil shares, are the forcing the PPS down and buying back ? Lets see if they do next reporting , Id bet they have already started , This IMO is pure Manipulation, The posts here daily bashing may work for them JMHO...
Votes:
2
0
57
Yahoo Finance
06/04
(Community Post)
**Johnson & Johnson Hematology Leadership:** While Geron Corporation now commercializes imetelstat, Johnson & Johnson ([**Janssen**](https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-hematology-leadership-with-30-presentations-at-the-2026-european-hematology-association-eha-congress)) remains a major stakeholder in multiple ongoing clinical trials showcased at EHA 2026...
Votes:
1
0
57
Yahoo Finance
06/04
(Community Post)
## QUIET? Here we are in the first week of June, the third month of Q2 and "things" seem very QUIET! So What??? Harout SHOULD HAVE some sort of idea of how Q2 has gone, maybe even a good idea. He should have some idea of what's happened to the "prescription count" and reports of progress or lack thereof from his sales force! NO, I don't think that anything much has happened with the EU. Rytelo's price will continue to be an issue! Maybe a few other "things" have happened/ transpired behind the scenes? Wouldn't this be a good time for a PR telling us about some "good" progress that Geron has made? Of course, IMO....
Votes:
1
0
57
Yahoo Finance
06/04
(Community Post)
Who knows if big Pharma companies understand value of Rytelo, JNJ was first to be partnered with GERN… could be in their best interests to acquire it after GERN demonstrated strength by being stand alone and being a profitable company in 2026....
Votes:
1
0
57
Yahoo Finance
06/04
(Community Post)
[@jeff46624](mention://user/1c84cd50-f2c1-4c33-a264-903aca1a9afe) Good find Jeff\. Here's what I found there\. Major holders that have opened new positions in Geron Corporation include Vanguard Capital Management Llc, Vanguard Portfolio Management Llc, Vanguard Fiduciary Trust Co, VANGUARD ASSET MANAGEMENT, Ltd, Vanguard Global Advisers, LLC, Toronto Dominion Bank, Vanguard Investments Australia, Ltd\., Hudson Bay Capital Management LP, Tiaa\-cref Individual & Institutional Services, Llc, Stembrook Asset Management, LLC, Prime Capital Investment Advisors, LLC, PlanVest Financial, Inc, Insigneo Advisory Services, Llc, Valeo Financial Advisors, LLC, Summit Financial Strategies, Inc\., Beacon Investment Advisory Services, Inc\., Alternative Investment Advisors, LLC\., Cassaday & Co Wealth Management LLC, Bare Financial Services, Inc, and JNBA Financial Advisors \....
Votes:
1
0
57
Yahoo Finance
06/04
(Community Post)
From Zacks: Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal. So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound....
Votes:
4
0
57
Yahoo Finance
06/04
(Community Post)
i present factual assessments from 30 years of predictable results and geron is an example of bad management fact question : how does management achieve double approval and run it into the ground from 5\.34 to 1\.04?? thats a fact and will retrace down to\.85 imo\.based on track record\....
57
Yahoo Finance
06/04
(Community Post)
## Interpretation (AI generated) - The **Kuykendall OS finding** is novel because it suggests a survival benefit from telomerase inhibition in MF, which is mechanistically plausible but not yet confirmed in large non‑US observational cohorts. - Without direct OS data from non‑US registries for imetelstat, it is difficult to confirm whether the OS prolongation is due to the drug’s effect or secondary to improved hematologic response and reduced transfusion burden. - In MF, OS is typically modestly prolonged with effective therapies, so a statistically significant OS gain in a phase 3 trial is clinically meaningful, but it must be validated in real‑world, multi‑center, non‑US data to confirm generalizability. **Next steps:** To fully compare, one would need to: - Extract OS data from non‑US MF registries for patients receiving imetelstat (if available). - Compare median OS, hazard ratios, and confidence intervals between the IMpactMF trial and registry cohorts. - Assess whether …...
Votes:
1
0
57
Yahoo Finance
06/04
(Community Post)
another question for my haters ,did you invest in a cancer cure or an EMPLOYMENT AGENCY ? experience show if there all newbies its uncontrolable like herding cats ,biggest mistake committed by management to the peril of shareholders was and remains the shelf and dilution\....
57
Yahoo Finance
06/04
(Community Post)
## From today's article... Geron \(GERN\) has been beaten down lately with too much selling pressure\. While the stock has lost 26\.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier\. The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term\. On the fundamental side, there has been strong agreement among the sell\-side analysts covering the stock in raising earnings estimates for the current year\. Over the last 30 days, the consensus EPS estimate for GERN has increased 55\.6%\. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term\....
Votes:
6
0
57
Yahoo Finance
06/04
(Community Post)
Hope some of you newbies bought the dip at 1.14 or 1.15. The complainers will not get rich. No triple-bagger for them. Harout is on the ball and no joke. He wants this pps to hit $4.00 by early 2027 for sure. Likely a lot sooner. The pps has been above $5 at least five time in last 30 years. Geron could not make the needed painful changes under JZ sale leadership. Harout was vetted by board and pulled in to right the tiller. Harout has the connections in US, EU, and Asia. Speaks 4 or more languages and knows cancer company operations very well. He knows how to use big pharma too for sales distribution and can jack up revenue when the pricing is set in favorable terms....
Votes:
2
0
57
Yahoo Finance
06/04
(Community Post)
## For PoP and John!!! Both of you posted that Harout KNOWS how the "game is played!" Well, Does He???????? REALLY?????? Look at Geron's candlestick chart from Aug 6, 2025, when Harout was hired, until today. What do you see? When Harout was hired, the PPS was at about a buck thirty-nine. What is the PPS today? It's a buck twenty-one as I post! In between, the PPS rose to 2 bucks, fell back and went up a couple times, only to fall back down to its current value! IN THE MEANWHILE, THE DOW AND NDQ REACHED RECORD HIGH, AFTER RECORD HIGH, AFTER RECORD HIGH!!! So, Harout knows how the "game is played?" Geeeee, you could have fooled me! Of course, IMO....
Votes:
4
0
57
Yahoo Finance
06/04
(Community Post)
incy printed $ 101\.24 gern printed 1\.21 and bmy printed $56\.60\. these three compete for the same sick patienthow about all three licence each other under the premise three can get to 5 billion faster than each can get to 1 billion , critical mass\....
57
Yahoo Finance
06/04
(Community Post)
IMO the EU launch would have happened by now if P3 MF results were further off , Thats the "" Catalyst"" No Q about it. So sit back and wait ot Hand over your shares to the giant Inst that are accumulating & look st May reporting inst are buying !! go to Fintel and look , nothing is going to happen until results come out Q2 watch GS closely they sold ok not the first time they sold and pps dropped to a buck , remember ? then they bought back in st lower lows 10-20-30-40 cents on millions of shares they are IMO SHAKING the tree , their worms are out daily to discourage investors , its obvious, JMHO...
57
Yahoo Finance
06/04
(Community Post)
## from Zacks recent article Gern due for Reversal Moreover, GERN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 Fair value is 6-7 X currrnt pps JMHO...
Votes:
1
0
57
Yahoo Finance
06/04
(Community Post)
## **AI Overview** At the **2026 European Hematology Association (EHA) Congress** [**EHA Congress 2026 | Parexel**](https://www.parexel.com/about-us/events/eha-congress-2026), **clinical data regarding the telomerase inhibitor imetelstat (Rytelo) [First Real-World Evidence Study of RYTELO® (imetelstat) in Lower- ...](https://ir.geron.com/node/18881/pdf)** is prominently featured [**Poster presentations at EHA 2026 | Parexel**](https://www.parexel.com/about-us/events/poster-presentations-eha-2026). Key real-world evidence and trial updates are being shared, focusing on lower-risk myelodysplastic syndromes (LR-MDS) First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026....
Votes:
3
0
57
Yahoo Finance
06/05
(Community Post)
**Hong Kong DengYue Medicine (DengYueMed)** has expanded its global innovative drug distribution portfolio by making **Rytelo (imetelstat)** available to patients and wholesale markets, with promotional offers reducing costs by **up to 50% off**...
Votes:
1
0
57
Yahoo Finance
06/05
(Community Post)
Yes, HongKong DengYue Medicine sells Rytelo \(imetelstat\)\. They list it as a distributed product on their website for the treatment of low\- to intermediate\-1 risk myelodysplastic syndromes \(MDS\) with transfusion\-dependent anemia\. HongKong DengYue Medicine is allowed to sell Rytelo \(imetelstat\) because they operate as a licensed international pharmaceutical wholesaler and re\-exporter, not a traditional retail consumer pharmacy\.They are legally permitted to distribute this medication globally based on three specific pillars:1\. Hong Kong Wholesale and Export LicensingGovernment Certification: DengYue Medicine holds official import, export, and wholesale licenses issued by the Hong Kong Department of Health\.The Re\-Export Framework: Hong Kong serves as a major global free\-trade hub for pharmaceuticals\. Under Hong Kong law, licensed wholesalers are permitted to source advanced therapies like Rytelo globally and legally re\-export them to other jurisdictions, pharmacies, and medical institutions\.2\. Supply Chain and Global Compliance FrameworkGood Distribution Practices \(GDP\): They operate under standard international pharmaceutical Good Distribution …...
Votes:
1
0
57
Yahoo Finance
06/05
(Community Post)
The iMpact study is mult-national. Early positive signs a huge catalyst in 2026 revenues. Geron has been put through the wringer on proof of drug working on large MDS population. Too many patients are getting ravaged by the disease by relying on the status quo drugs. It will be great to see Rytelo sales increase in EU and Asia. Their cancer physicians will Re-affirm the effectiveness of imetelstat halting the disease, not just a bandaid on symptoms like many US drugs....
Votes:
6
0
57
Yahoo Finance
06/05
(Community Post)
## **AI Overview** **DengYueMed** facilitates global access to **Rytelo** (imetelstat), **an FDA-approved telomerase inhibitor for treating transfusion-dependent anemia in low- to intermediate-1 risk Myelodysplastic Syndromes (MDS)**. The platform serves as an international importer/wholesaler for specialty and hard-to-find medications....
Votes:
1
0
57
Yahoo Finance
06/05
(Community Post)
## Don't mess with the tutes too long. From AI on Soleus' new position in Geron, with RA Capital's nearly 10% ownership: "Notably, RA Capital shares a substantial percentage of its portfolio with Soleus Capital — these two funds frequently co-invest and likely coordinate. Institutional InvestorTracxn That last point is really important for you. RA Capital and Soleus appear to be aligned investors with overlapping strategies. If Soleus pushes for a sale, RA Capital is likely to be supportive rather than opposed. Together they control roughly 16% of Geron — that's enormous combined leverage over the board...
Votes:
5
0
57
Yahoo Finance
06/05
(Community Post)
## 2 year anniversary of the approval Bears can say the glass is half full and revs should be higher by now but I say these things take time and it is actually just now beginning to bear fruit so..... Anyone selling now is a fool...
Votes:
4
0
57
Yahoo Finance
06/05
(Community Post)
Buy Gerny on fear. We lost many more retail to this in last few months. Next time, Gerny hits $2, it will not look back and keep going up, up, up! ...
Votes:
1
0
57
Yahoo Finance
06/05
(Community Post)
Royalty Pharma will present next week. The better Geron does, the more they share on rytelo royalties. Win-Win! Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET. ...
Votes:
2
0
57
Yahoo Finance
06/05
(Community Post)
Mark this post, IMO there will come a day in near term when P3 is released the worms will crawl back under the rock they come from. Right now were in a wait and see mode. Ask Chatgpt why they have not partnered with a EU co yet, The value of this co is currently unrecognized , IF & That's is a IF MF P3 results and OS are better than current care , Its a game changer for Gern. Risk-Reward. and from what i see from May Inst reporting they are accumulating !...
Votes:
3
0
57
Yahoo Finance
06/05
(Community Post)
## FROM CHAT My Fair Value Assessment Based on: - RYTELO revenue growing from $184M in 2025 and guided to $220–240M in 2026, - Q1 2026 revenue growth continuing sequentially, - Over $300M cash remaining on the balance sheet, - Potential value from the Phase 3 IMpactMF trial, I estimate **current fundamental fair value around $3.00 per share**, with a reasonable range of **$2.50–$4.00**. That is broadly consistent with the analyst median target. What Could Change Fair Value? **Increase fair value to $5–$8+:** - Strong acceleration of RYTELO prescriptions - European partnership with significant upfront cash - IMpactMF Phase 3 showing overall survival benefit near or above 30 months - Path toward profitability **Reduce fair value below $2:** - Slower-than-expected commercial uptake - Need for additional capital raises - Weak IMpactMF efficacy signals Given what is known today, I view **$3.00/share as a reasonable fair value estimate**, with the stock …...
57
Yahoo Finance
06/05
(Community Post)
- Analyst targets range from $1 to $5, with averages around $2.50–$3.40. ## Scenario 1: Commercial Success Only Assumes: - RYTELO continues growing. - No major MF upside yet. - No EU deal. Probability: **35%** Estimated Value: - 2027: $2.50–$3.50 - 2028: $3.00–$4.50 ## Scenario 2: EU Partnership Assumes: - Commercial growth continues. - Geron signs a European partner with meaningful upfront payment. Probability: **25%** Estimated Value: - Upfront payment potentially worth hundreds of millions. - Removes need to build a large EU infrastructure. Estimated Value: - 2027–2028: $4–$6 ## Scenario 3: Positive IMpactMF Phase 3 Assumes: - Statistically significant survival benefit. - Overall survival approaches or exceeds 30 months. - Regulatory path opens for MF indication. Probability: **30%** Estimated Value: - 2028: $6–$10+ This is the largest value driver because the MF market opportunity is substantially larger than lower-risk MDS....
Votes:
1
0
57
Yahoo Finance
06/05
(Community Post)
[@jeff46624](mention://user/1c84cd50-f2c1-4c33-a264-903aca1a9afe)....Jeff....are you starting to get tired of all the winning you have been achieving??? Donny is tired of all the winning too!!! 🤣 ...
57
Yahoo Finance
06/05
(Community Post)
## Scenario 4: Acquisition Potential acquirers often discussed by investors include large hematology/oncology companies such as Johnson & Johnson, Bristol Myers Squibb, or Novartis. Probability: **10%** Estimated Buyout Range: - $5–$12 per share - Could be higher if MF data are exceptionally strong. ## Probability-Weighted Fair Value ScenarioProbabilityValueCommercial only35%$3.50EU partnership25%$5.00MF success30%$8.00Acquisition10%$10.00 Weighted fair value ≈ **$5.50/share** My Current Assessment - **Conservative fair value:** $3.00–$4.00 - **Probability-weighted fair value:** \~$5.50 - **Bull case (MF success + partnership):** $8–$12+ - **Extreme bull case (strong MF data + acquisition):** $12–$15+ The single most important catalyst remains the IMpactMF Phase 3 readout. If overall survival trends continue toward the \~30-month range discussed by investors, that could dramatically increase Geron's valuation relative to where the stock trades today...
57
Yahoo Finance
06/05
(Community Post)
## If OS Remains Near 30 Months If evidence before the readout continues to suggest median overall survival around 30 months or better, I would increase my estimate to: OutcomeProbabilityPositive Phase 345%Strongly positive Phase 325% Combined success probability: **\~70%**. What the Market Appears to Be Pricing In With GERN trading around the low-$1 range, the market does **not** appear to be pricing in a 70% chance of Phase 3 success. The valuation suggests investors remain concerned about: - Commercial execution of RYTELO, - Timing of profitability, - And uncertainty around IMpactMF. If IMpactMF ultimately demonstrates a robust overall survival benefit approaching the Phase 2 observations, the stock's valuation could change substantially because the myelofibrosis opportunity is much larger than the currently approved lower-risk MDS indication. Based on the totality of the Phase 2 data and current information, I would place the probability of an approvable Phase 3 outcome closer to …...
57
Yahoo Finance
06/05
(Community Post)
## What Does 82% Mean? If 82% is accurate, it means approximately: - Public float is overwhelmingly controlled by institutions. - Retail investors own less than 20% of outstanding shares. - Daily trading is heavily influenced by fund activity. For a small-cap biotech, **82% institutional ownership would actually be extremely high and generally considered a positive signal**, because sophisticated investors control most of the stock. What I Think the Real Number Is Based on recent filings, I believe the true figure is likely somewhere in the: **75%–82% range** rather than precisely one number. The exact percentage changes almost daily as: - New 13F filings arrive, - Shares outstanding change, - ETFs rebalance, - Funds add or reduce positions. The More Important Question The key issue is not whether ownership is 76% or 82%. The important question is: **Is institutional ownership increasing or decreasing?** **Based on the latest filing cycle, ownership …...
57
Yahoo Finance
06/05
(Community Post)
[@john03324](mention://user/665d1511-2814-4467-8f19-7b7b53073e94).....looks like the Shorts are living the dream to me!!! 🤣 ...
Votes:
3
0
57
Yahoo Finance
06/05
(Community Post)
Based on the latest available SEC filings, **Goldman Sachs has not sold all of its GERN shares.** The most recent reported position I could verify shows Goldman holding approximately **16.17 million shares of Geron** as of the latest disclosed filing, representing about **2.5% of the company.** What's interesting is that Goldman's position appears to have changed significantly over time: - Earlier reports and some data aggregators showed Goldman increasing its position substantially during prior quarters. - The latest institutional ownership data I found shows Goldman still holding **16.2 million shares**, but that position was reported as **24.1% lower than the prior filing**, meaning they reduced the stake but did **not** exit completely. My Take The evidence suggests: - **No, Goldman did not sell all of its GERN shares.** - They appear to have **trimmed** a sizable position. - A remaining position of \~16 million shares is still large enough to …...
Votes:
1
0
57
Yahoo Finance
06/05
(Community Post)
[@jeff46624](mention://user/1c84cd50-f2c1-4c33-a264-903aca1a9afe)....are you capable of posting original thoughts or does AI control your life??? 🤣 ...
Votes:
1
0
57
Yahoo Finance
06/05
(Community Post)
[@jeff46624](mention://user/1c84cd50-f2c1-4c33-a264-903aca1a9afe).....Goldman must be tired of all the winning too since they still have shares of Gercon right??? 😂 ...
Votes:
4
0
57
Yahoo Finance
06/05
(Community Post)
[@u_xmfyx8kyc6pq](mention://user/68a8c4d0-f594-491e-8746-b16f4cff3881) whats interesting is all these ai pump posts and the stock is at 1.17 a share so not very effective for longs, seems like its having an opposite effect...
Votes:
3
0
57
Yahoo Finance
06/05
(Community Post)
Institutions build their stakes in biotech firms like Geron through five primary tactical pathways: 1\. Algorithmic Market Accumulation \(VWAP/TWAP\)To accumulate millions of shares without alerting the retail market or triggering momentum algorithms, institutions use advanced Execution Management Systems \(EMS\)\.Time\-Weighted Average Price \(TWAP\): Splitting a massive order into equal, tiny slices executed at regular intervals throughout the trading day\.Volume\-Weighted Average Price \(VWAP\): Matching buying patterns to the stock's historical intraday volume profile—buying more when liquidity is high and tapering off when volume dries up\. 2\. Utilizing Dark Pools and Block TradesLarge healthcare funds frequently buy shares away from public exchanges like the NASDAQ to hide their footprints\.Dark Pools: Alternative Trading Systems \(ATS\) where institutions trade large blocks of Geron shares anonymously\. The trade execution price is only printed to the public tape after the transaction is complete, completely avoiding premature price appreciation\.Block Crosses: Broker\-dealers \(like Goldman Sachs or Jefferies\) act as …...
57
Yahoo Finance
06/05
(Community Post)
## You got to love these Baggies 🤣:  [**Jeff**](https://finance.yahoo.com/community/u/jeff46624/) [@jeff46624](https://finance.yahoo.com/community/u/jeff46624/) [2h](https://finance.yahoo.com/community/post/0a321c64-b00e-41fd-abf2-d8330ac475f8/comment/78ab24d7-6216-4e66-9dde-befbba5ec479/#comments) [**@short22052**](https://finance.yahoo.com/community/u/short22052/) I buy on dips Worm, as does your bosses , BTW its not raining, crawl back under ,,,,,,,,Shorting a cancer cure, Cant get any lower IQ that your boy JB Or Kamala Lets hope she and AOC run in 2028 praying !!...
Votes:
2
0
57
Yahoo Finance
06/05
(Community Post)
Let our boy do his work. He is not even a year into turning the ship around. He completely changed the culture in the first six months to the pay for performance approach. You help get more business and your options are not underwater and may be worth quite a bit....
Votes:
1
0
57
Yahoo Finance
06/05
(Community Post)
[@jim1031](mention://user/3f920880-4925-4443-80a3-27dfab901607) jim: The reason that you may get your Geron Trade Order filled next week IS BECAUSE Harout has NOT been doing a GOOD JOB!!! If he had been performing, you would NOT be able to buy at this LOW price! Of course, IMO....
Votes:
3
0
57
Yahoo Finance
06/05
(Community Post)
## What a terrible day for the NDQ Exchange! It was down 1,450 points! The ONLY stock on my watch list that was Green was Home Depot (HD), up 83 cents! I suppose that we should be glad that GERN wasn't down more than 4 pennies!!! Of course, IMO....
Votes:
3
0
57
Yahoo Finance
06/05
(Community Post)
Did anybody get filled today at $1.16? Just missed $1.15 fill. Was hoping the downers could debby downer it 1.15. Oh well. Another week coming up. 17 more trading days till magical quarter 3. New retail, existing tutes, and heggies like Goldman can pick up more discounted cheese....
Votes:
2
0
57
Yahoo Finance
06/05
(Community Post)
## RYTELO’s Strong Features in Combination Therapy RYTELO (imetelstat) is an **FDA‑approved oligonucleotide telomerase inhibitor** for adults with **low‑ to intermediate‑1 risk myelodysplastic syndromes (MDS)** who have transfusion‑dependent anemia and are ESA‑ineligible, ESA‑relapsed, or ESA‑refractory [www.accessdata.fda.gov](http://www.accessdata.fda.gov)[**+1**](https://www.bing.com/ck/a?!&&p=30984873dfbbeba8f3e2aeddb1a665a43c5efc657f3baab627482ec2b7977212JmltdHM9MTc4MDYxNzYwMA&ptn=3&ver=2&hsh=4&fclid=197b290f-dad1-670f-1c98-3f40db5d66c7&u=a1aHR0cHM6Ly93d3cuYWNjZXNzZGF0YS5mZGEuZ292L2RydWdzYXRmZGFfZG9jcy9sYWJlbC8yMDI0LzIxNzc3OXMwMDBsYmwucGRm&ntb=1). Its combination potential is strongest in **second‑line treatment** for lower‑risk MDS, where it can be used alongside supportive care and other agents. **Key combination‑friendly features:** 1. **First‑line option after ESAs** RYTELO is the **only FDA‑approved treatment** for transfusion‑dependent anemia in lower‑risk MDS after ESAs for use in ESA‑ineligible patients [www.rytelohcp.com](http://www.rytelohcp.com). This positions it as a direct successor to ESA therapy, making it a natural fit in sequential treatment plans. 2. **High transfusion independence rates** In the IMerge trial, **39.8%** of ESA‑relapsed/refractory patients achieved ≥8 consecutive weeks without RBC transfusions vs. 15% with placebo [www.rytelohcp.com](http://www.rytelohcp.com). This strong hematologic response supports its use in combination with supportive care (e.g., iron chelation, myeloid growth factors) to manage …...
Votes:
2
0
57
Yahoo Finance
06/05
(Community Post)
[@louis3807](mention://user/819ab20a-6f47-4e0a-86c1-dcf592e7befc).....so you are just going to slop it up??? are capable of any original thoughts??? 😂 ...
Votes:
1
0
57
Yahoo Finance
06/05
(Community Post)
**Results:** In the overall imetelstat cohort (n = 107), median age was 76.5 years, and median baseline hemoglobin was 7.8 g/dL, 35 patients (32%) had ring sideroblasts. Most patients had significant prior therapy and transfusion with 74% previously exposed to luspatercept. In this population, the probabilities of achieving TI were 30.2% at 8 weeks and 26.6% at 20 weeks after imetelstat initiation....
57
Yahoo Finance
06/05
(Community Post)
I actually hope Soleus Capital does become an activist investor after the IMpactMF trial receives a continuation from the IDMC. Why? Here's where you and I part company: If the IDMC grants the IMpactMF trial a continuation without modifications, Geron's share price will rise, not fall as you claim, because it will be a relief to find that there's no futility and the whole waiting period will be over. If soon after, Soleus pushes for a buyout, the price will stay up as rumors circulate about the strength of the hazard ratio and p value, as I believe they will be good. With so many Big Pharmas' patents' expiring, there will be a fiery bidding war between two or more Big Pharmas for Geron, whose Rytelo patents are long-term and extendable....
Votes:
2
0
57
Yahoo Finance
06/05
(Community Post)
[@stockpicker5321](mention://user/aeb8369f-3cf2-4fea-82ce-e19f1d162189) The IMpactMF trial officially started on April 12, 2021\. So it's safe to say safety is not an issue\. As for futility or efficacy that we won't find out until the interim readout is done because that is the only time the IDMC will take a look at that until the final readout, unless we are halted for efficacy\. This halt in the readout is what everyone is hoping for and management is preparing for\. To have to continue to the final, although that in itself is positive but the Shorts would prey upon the share price touting dilution\. Put me in the camp that we will be punished if we go to the final readout in two years time\....
57
Yahoo Finance
06/05
(Community Post)
i noticed on this yahoo app site that yahoo prints that geron still has 258 employees \. i was under the impression we were brooming 86 \. or maybe they gave 86 new hires a new broom my mistake i added to my position because of the above \....
57
Yahoo Finance
06/06
(Community Post)
The last several days were quite entertaining with all the AI and touting! All of this activity for a stock nearing a PPS of a Buck!!! A Single Buck!!! I got a kick out of the comment that Harout has ONLY been CEO for about 10 months?!?!? What a joke! How much time are you going to give him? He should have made some progress by now but the PPS is down from when he came onboard! Negative Progress does NOT count! I would like the touters to answer why the Q2 Net Revenue of about $52Million wasn't considered a "good" Market sign? It certainly seems like the Markets simply ignored that metric? Why? So, let the touting and AI continue and maybe use a few circus figures to boot to introduce the post! Of course, IMO....
Votes:
1
0
57
Yahoo Finance
06/06
(Community Post)
[@u_dns1q1tcdc8s](mention://user/2e56efee-38ae-4da3-b177-9f3e514400a2) master: Remember that Harout hired a bunch of High Priced VP's, Executives and Account Managers! Maybe the New Hire numbers equals the number given the "broom!" Fact not Fiction!...
Votes:
1
0
57
Yahoo Finance
06/06
(Community Post)
From Hodl: "The IMpactMF trial officially started on April 12, 2021" So, Why After 5 Years haven't we reached the magic event number of 112/114 or whatever it is? Can Rytelo be working so well, that the patients are living for years and years? Or, did ole chippy take "forever" to fully populate the trial? Of course, IMO....
Votes:
2
0
57
Yahoo Finance
06/06
(Community Post)
Rytelo & Combinations **AI Summary:** RYTELO’s strong combination features include its **FDA‑approved second‑line role after ESAs**, **high transfusion independence rates**, **compatibility with supportive care**, and **NCCN Category 1 status**. These make it a valuable component in multimodal MDS management, especially for ESA‑ineligible or relapsed/refractory patients, when integrated with transfusion support, growth factors, and other agents....
Votes:
1
0
57
Yahoo Finance
06/06
(Community Post)
[@louis3807](mention://user/819ab20a-6f47-4e0a-86c1-dcf592e7befc)..... do you really think posting AI Slop is going to convince investors to buy this junk??? What are nervous about??? 😂 ...
57
Yahoo Finance
06/06
(Community Post)
Re IMpactMF ## First Registration Date: The trial was originally registered on ClinicalTrials.gov on April 12, 2021. December 2023: Reached 50% enrollment. August 2024: Reached 70% enrollment. December 2024: Reached approximately 75% enrollment across 172 global sites. July 2025: Reached over 95% enrollment. September 2025: Full enrollment completed with a final total of 320 to 327 randomized patients\. Rytelo Arm \(Arm A\): 214 patients assigned to receive imetelstat at 9\.4 mg/kg via intravenous infusion every 21 days\. BAT Arm \(Arm B\): 106 patients assigned to receive investigator\-selected non\-JAK inhibitor therapies\. Because this trial specifically targets patients who are relapsed or refractory to Janus kinase inhibitors \(JAKi\), all JAK inhibitors are completely excluded from the BAT arm\. Instead, investigators select from standard, non\-targeted treatments: Hydroxyurea \(most common for cytosis control\) Immunomodulatory drugs \(e\.g\., thalidomide\) Androgens \(e\.g\., danazol for anemia control\)Hypomethylating agents or standard chemotherapyInterferon therapies Crossover ProvisionCrossover is permitted: Patients randomized …...
Votes:
1
0
57
Yahoo Finance
06/06
(Community Post)
[@hodl69](mention://user/c3358603-47ae-41ef-901f-95765a40340e) Hodl: Thank you for the data/ metrics! Just as I thought, ole failed chippy took OVER 4 years to get JUST about 327 candidate patients into the MF trial! And, that was from World Wide Selection! That time is ABSOLUTELY RIDICULOUS!!! And, PoP blames it on the Covid 19! LOL!!! Fact not Fiction!...
Votes:
1
0
(Community Post)